Eventually most people with type 2 diabetes (T2D) require insulin replacement therapy. Despite introduction of novel therapies, insulin remains a critical therapy for the management of diabetes. Basal and mealtime insulin is often required to achieve glucose control.
Interference of injections with daily activities, injection pain, and embarrassment make adherence difficult.
Our mission is to provide multi-day, simple, wearable delivery devices that will improve the lives of people living with diabetes by freeing them from insulin injections and enabling them to take control.
We are dedicated to helping people with diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life.
CeQur has a platform of simple wearable 3-day devices that have been developed to provide the benefits of newer technologically advanced insulin therapies without their complexity and up-front expense. These devices have been designed to reduce the barriers and challenges of daily insulin injection therapy to enable people to achieve target glycemic control.
CeQur is headquartered in Horw, Switzerland, with operations in Cardiff, United Kingdom and Marlborough, Massachusetts.
EVP & Chief Financial Officer